JP2006502228A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502228A5
JP2006502228A5 JP2004543559A JP2004543559A JP2006502228A5 JP 2006502228 A5 JP2006502228 A5 JP 2006502228A5 JP 2004543559 A JP2004543559 A JP 2004543559A JP 2004543559 A JP2004543559 A JP 2004543559A JP 2006502228 A5 JP2006502228 A5 JP 2006502228A5
Authority
JP
Japan
Prior art keywords
vaccine composition
hiv
composition according
plg
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004543559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031935 external-priority patent/WO2004032860A2/en
Publication of JP2006502228A publication Critical patent/JP2006502228A/ja
Publication of JP2006502228A5 publication Critical patent/JP2006502228A5/ja
Pending legal-status Critical Current

Links

JP2004543559A 2002-10-07 2003-10-07 Ｈｉｖワクチン処方物 Pending JP2006502228A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41657302P 2002-10-07 2002-10-07
PCT/US2003/031935 WO2004032860A2 (en) 2002-10-07 2003-10-07 Hiv vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011226126A Division JP2012012416A (ja) 2002-10-07 2011-10-13 Ｈｉｖワクチン処方物

Publications (2)

Publication Number Publication Date
JP2006502228A JP2006502228A (ja) 2006-01-19
JP2006502228A5 true JP2006502228A5 (enExample) 2006-11-24

Family

ID=32093869

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004543559A Pending JP2006502228A (ja) 2002-10-07 2003-10-07 Ｈｉｖワクチン処方物
JP2011226126A Pending JP2012012416A (ja) 2002-10-07 2011-10-13 Ｈｉｖワクチン処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011226126A Pending JP2012012416A (ja) 2002-10-07 2011-10-13 Ｈｉｖワクチン処方物

Country Status (7)

Country Link
US (3) US20060110736A1 (enExample)
EP (1) EP1565583A4 (enExample)
JP (2) JP2006502228A (enExample)
AU (1) AU2003282498A1 (enExample)
CA (2) CA2501476A1 (enExample)
WO (1) WO2004032860A2 (enExample)
ZA (1) ZA200503554B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4705591B2 (ja) * 2004-01-07 2011-06-22 バイオメディカル リサーチ モデルズ， インコーポレイテッド 抗原または免疫原に対する免疫応答を仕立てる方法。
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP2314232B1 (en) 2006-10-17 2015-03-25 Covidien LP Apparatus for applying surgical clips
US20120258540A1 (en) * 2006-11-13 2012-10-11 Georgia Tech Research Corporation Methods for modifying virus surfaces
HRP20120433T1 (en) * 2007-10-19 2012-07-31 Novartis@Ag Meningococcal vaccine formulations
US20110208212A1 (en) * 2010-02-19 2011-08-25 Zergiebel Earl M Surgical clip applier
US9358015B2 (en) 2008-08-29 2016-06-07 Covidien Lp Endoscopic surgical clip applier with wedge plate
US8403945B2 (en) 2010-02-25 2013-03-26 Covidien Lp Articulating endoscopic surgical clip applier
US8932575B2 (en) 2010-09-21 2015-01-13 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
US9011464B2 (en) 2010-11-02 2015-04-21 Covidien Lp Self-centering clip and jaw
US9186153B2 (en) 2011-01-31 2015-11-17 Covidien Lp Locking cam driver and jaw assembly for clip applier
US9532787B2 (en) 2012-05-31 2017-01-03 Covidien Lp Endoscopic clip applier
EP2941269B1 (en) 2013-01-07 2020-12-09 Mucosal Vaccine Technologies LLC Therapeutic vaccines for treating herpes simplex virus type 2 infections
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018129270A1 (en) * 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6171596B1 (en) * 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (es) * 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
WO2000006123A1 (en) * 1998-07-29 2000-02-10 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6099847A (en) * 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AUPQ520800A0 (en) * 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US20030138453A1 (en) 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
WO2002026212A2 (en) * 2000-09-28 2002-04-04 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
EP1409694A4 (en) * 2001-07-05 2006-02-08 Chiron Corp POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
AU2002320314A1 (en) * 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20050191358A1 (en) * 2003-01-14 2005-09-01 Derek O' Hagan Microparticles with adsorbed polynucleotide-containing species
CN102847538B (zh) 2007-07-06 2016-07-06 M技术株式会社 由球碳形成的结晶的制造方法及制造装置

Similar Documents

Publication Publication Date Title
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
Taslimi et al. Leishmaniasis and various immunotherapeutic approaches
Halperin et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
Salonius et al. The road to licensure of a DNA vaccine
TWI917342B (zh) 免疫刺激組合物及其用途
Tomai et al. TLR7/8 agonists as vaccine adjuvants
Higgins et al. Immunostimulatory DNA as a vaccine adjuvant
EP1322287B1 (en) Microparticles for delivery of the heterologous nucleic acids
JP2007523863A5 (enExample)
JP2010519205A5 (enExample)
RU2006106848A (ru) Улучшения в вакцинации
Zhang et al. Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice
JP2011026328A (ja) オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
JP2001526688A (ja) オリゴヌクレオチドアジュバント
TW200307557A (en) Stabilized synthetic immunogen delivery systems
JP2006020648A5 (enExample)
MX2011012147A (es) Inmunoterapia de vacuna.
CN110612118A (zh) 用于引起针对hbv的免疫应答的病毒样粒子
JP2008000001A (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
CN100425287C (zh) 肿瘤疫苗
US8734806B2 (en) Immunogenic composition and use thereof
JP2003530088A5 (enExample)
Stephen et al. Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys
WO2017021266A1 (en) Enhanced immune response in porcine species
JP7271433B2 (ja) 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用